Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Seed Fonds III für die Region Aachen is a German venture capital fund focused on providing seed and early-stage financing to technology-oriented startups in the Aachen, Krefeld, and Mönchengladbach regions. Managed by the S-UBG Group, the fund targets high-growth sectors including biotechnology, medical technology, and information technology. It plays a critical role in the regional ecosystem by supporting the commercialization of academic research and innovative technologies from institutions like RWTH Aachen University. Notable portfolio companies include Protembis, aquila biolabs, and Hemovent. The fund has been succeeded by TechVision Fonds I, which continues its investment strategy with a broader regional and stage focus.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Seed Fonds III.